HilleVax Pre-IPO: Lead Candidate Has Potential to Become First Approved Vaccine for Norovirus
Norovirus vaccine developer, Hillevax, formed by Takeda Pharmaceutical and PE firm Frazier Healthcare Partners, is seeking to raise up to $100 million through its Nasdaq IPO.
- HilleVax (HLVX US), a novel vaccine developer intends to raise $100 million through an IPO. Its lead program HIL-214, intended to prevent norovirus infection is in phase 2 clinical trial.
- The number of shares to be offered and the price range are yet to be disclosed. Post listing, the company will trade under the ticker HLVX on the Nasdaq.
- HIL-214’s large addressable market, with huge unmet need, HilleVax’s earlier fund-raising history, and Takeda’s backing are some of the positives of this new offering.
By Tina Banerjee - https://www.smartkarma.com/profiles/tina-banerjee?utm_source=tiger_community
On HilleVax (HLVX US) - https://www.smartkarma.com/entities/hillevax-inc?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Nice
Ok
Ok